Transdermal immunization using solid-in-oil nanodispersion with CpG oligodeoxynucleotide adjuvants

Pharmaceutical Research

Volumn 32, Issue 4, 2015, Pages 1486-1492

  Kitaoka, Momoko ^a   Naritomi, Ayaka ^a   Hirakawa, Yuya ^a   Kamiya, Noriho ^a   Goto, Masahiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CpG oligodeoxynucleotide; solid in oil nanodispersion; transcutaneous immunization; transdermal drug delivery; vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; FLUORESCENT DYE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; ODN 1585; ODN 1668; OVALBUMIN; UNCLASSIFIED DRUG; CPG-OLIGONUCLEOTIDE; EMULSION; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; OLIGODEOXYRIBONUCLEOTIDE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISPERSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INVESTIGATIVE PROCEDURES; MALE; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN SECRETION; SKIN PERMEABILITY; SOLID IN OIL NANODISPERSION; SUSTAINED DRUG RELEASE; TH1 TH2 BALANCE; VACCINATION; ANIMAL; BLOOD; CHEMISTRY; EMULSION; IMMUNIZATION; IMMUNOLOGY; INBRED MOUSE STRAIN; INTRADERMAL DRUG ADMINISTRATION; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; EMULSIONS; IMMUNIZATION; IMMUNOGLOBULIN G; MALE; MICE, INBRED STRAINS; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; VACCINES;

EID: 84925484586     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1554-5     Document Type: Article

References (31)

1. Mishra DK, Dhote V, Mishra PK. Transdermal immunization: Biological framework and translational perspectives. Expert Opin Drug Deliv. 2013;10:183-200.
2. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum Vaccine. 2011;7(8):811-27.
3. Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr Opin Immunol. 2014;27C:26-32.
4. Mishra N, Gupta PN, Khatri K, Goyal AK, Vyas SP. Edible vaccines: A new approach to oral immunization. Indian J Biotechnol. 2008;7:283-94.
5. Jabbal-Gill I. Nasal vaccine innovation. J Drug Target. 2010;18(10):771-86.
6. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7(23):1184-9.
7. Seid Jr RC, Look JL, Ruiz C, Frolov V, Flyer D, Schafer J, et al. Transcutaneous immunization with intercell's vaccine delivery system. Vaccine. 2012;30(29):4349-54.
8. Li N, Peng LH, Chen X, Nakagawa S, Gao JQ. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine. 2011;29(37):6179-90.
9. Alexander A, Dwivedi S, Ajazuddin, Giri TK, Saraf S, Saraf S, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release. 2012;164(1):26-40
10. Lee MY, Shin MG, Yang VC. Transcutaneous antigen delivery system. BMB Rep. 2013;46(1):17-24.
11. Kitaoka M, Imamura K, Hirakawa Y, Tahara Y, Kamiya N, Goto M. Sucrose laurate-enhanced transcutaneous immunization with a solid-in-oil nanodispersion. Med Chem Commun. 2014;5(1):20-4.
12. Tahara Y, Kamiya N, Goto M. Solid-in-oil dispersion: A novel core technology for drug delivery systems. Int J Pharm. 2012;438(1-2):249-57.
13. Kitaoka M, Imamura K, Hirakawa Y, Tahara Y, Kamiya N, Goto M. Needle-free immunization using a solid-in-oil nanodispersion enhanced by a skin-permeable oligoarginine peptide. Int J Pharm. 2013;458(2):334-9.
14. Tahara Y, Namatsu K, Kamiya N, Hagimori M, Kamiya S, Arakawa M, et al. Transcutaneous immunization by a solid-in-oil nanodispersion. Chem Commun. 2010;46(48):9200-2.
15. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8(3):223-46.
16. Roberts TL, Sweet MJ, Hume DA, Stacey KJ. Cutting Edge: Species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol. 2005;174(2):605-8.
17. Sugita K, Kabashima K, Atarashi K, Shimauchi T, Kobayashi M, Tokura Y. Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin. Clin Exp Immunol. 2007;147(1):176-83.
18. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4(4):249-58.
19. Vabulas RM, Pircher H, Lipford GB, Häcker H, Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol. 2000;164(5):2372-8.
20. Ziegler A, Heidenreich R, Braumüller H, Wolburg H, Weidemann S, Mocikat R, et al. EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood. 2009;113(15):3494-502.
21. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009;61(3):256-62.
22. Mishra D, Mishra PK, Dubey V, Nahar M, Dabadghao S, Jain NK. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur J Pharm Sci. 2008;33:424-33.
23. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997;186(10):1623-31.
24. Lin L, Gerth AJ, Peng SL. GpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MyD88. Eur J Immunol. 2004;34(5):1483-7.
25. Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release. 2002;85(1-3):247-62.
26. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine. 1999;17(1):19-25.
27. Inoue J, Yotsumoto S, Sakamoto T, Tsuchiya S, Aramaki Y. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice. Pharm Res. 2005;22(10):1627-33.
28. Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8; T-cell responses in vitro. Blood. 2004;103(6):2162-9.
29. Schattenberg D, Schott M, Reindl G, Krueger T, Tschoepe D, Feldkamp J, et al. Response of human monocyte-derived dendritic cells to immunostimulatory DNA. Eur J Immunol. 2000;30(10):2824-31.
30. Slütter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA. Adjuvant effect of cationic liposomes and CpG depends on administration route. J Control Release. 2011;154(2):123-30.
31. Tahara Y, Honda S, Kamiya N, Piao H, Hirata A, Hayakawa E, et al. A solid-in-oil nanodispersion for transcutaneous protein delivery. J Control Release. 2008;131:14-8.